Our studies support a previously unrecognized therapeutic potential for M1R antagonists in the treatment of peripheral neuropathies and unravels a novel pathway of cholinergic signaling mediated via control of microtubule dynamics through Gα13 signaling. Here, CHRM1 is linked to peripheral neuropathy.